We evaluated a newly developed solid-phase immunoassay (EIA) of terminal deoxynucleotidyl transferase (TdT, EC 2.7.7.3) and compared it with the enzymatic assay of TdT involving DNA polymerase. We assessed the precision, performance characteristics, and clinical efficacy of the EIA procedure, using 249 specimens of peripheral blood and bone marrow and 118 specimens of whole blood. On linear regression analysis of results for these 249 samples as measured by the two procedures, the correlationcoefficient was 0.87. Distribution of TdT in mononuclear cells isolated from whole blood and bone marrow of subjects in several disease categories indicated good concordance between the two assay procedures. The EIA procedure is precise, can be performed on whole blood without first isolating mononuclear (14) . 1 In a study of the classffication of leukemia and lymphoma cells, McCaffrey et al. (5) observed that blast cells of a child with acute lymphocytic leukemia (ALL) contained a unique DNA polymerase, which was TdT. By either enzymatic (6-9) or iminunocytochemical (6, 10-13) assays for TdT, nonleukemic individuals are seen to have low or undetectable amounts of the TdT in their lymphocytes, whereas greater amounts are generally present in certain leukemias and lymphomas (5-8, 14, 15). The presence of TdT-positive blasts is a useful discriminator between acute lymphoid leukemia and acute myeloid leukemia (6, 11, 16, 17).
is a DNA polymerase that catalyzes end-addition of deoxynucleoside monophosphates to primer DNA. Unlike most DNA polymerases, TdT does not require a template (14) . 1 In a study of the classffication of leukemia and lymphoma cells, McCaffrey et al. (5) observed that blast cells of a child with acute lymphocytic leukemia (ALL) contained a unique DNA polymerase, which was TdT. By either enzymatic (6-9) or iminunocytochemical (6, 10-13) assays for TdT, nonleukemic individuals are seen to have low or undetectable amounts of the TdT in their lymphocytes, whereas greater amounts are generally present in certain leukemias and lymphomas (5-8, 14, 15) . The presence of TdT-positive blasts is a useful discriminator between acute lymphoid leukemia and acute myeloid leukemia (6, 11, 16, 17) .
TdT activity has been measured by biochemical assays (1, 
MaterIals and Methods
Enzyme immunoassay for TdT: All reagents needed to perform this assay are supplied in kit form by Abbott Laboratories. The procedure has been previously described (20) and is summarized in the package insert supplied by Abbott Laboratories.
Subjects: Using the Abbott TdT-EIA procedure, we assayed TdT in 249 blood lymphocyte and bone-marrow samples and 118 whole-blood specimens. Patients under 15 years of age provided approximately 85% of the ALL samples, 50% of the AML samples, and 50% of the normal and nonleukemic blood-disorder samples.
Peripheral blood and bone-marrow specimens for confirmation of reference interval limits were respectively specimens from normal donors to the bloodbank and specimens collected from patients with nonleukemic disorders and sent to the laboratory for purposes other than TdT evaluation. Bone-marrow specimens from normal volunteers were unavailable. We collected 26 whole-blood specimens from normal volunteers and from seven patients with nonleukemic disease. Bone-marrow specimens from eight patients (seven myelodysplasia and one autoimmune disease) with nonmalignant disease were collected and assayed for TdT by EIA.
Isolation of mononuclear cells from bone marrow and peripheral blood: Mononuclear cells (MNC) were isolated from bone marrow and peripheral blood by a standard flotation technique (26) . We aspirated the cells from the interface, washed, and resuspended them in isotonic saline (NaC1, 150 mmol/L), then made the cell counts. Details of the MNC preparation and analysis of whole-blood samples are described in the package insert supplied by Abbott Laboratories. Cell preparation for assay of TdT by the enzymatic polymerase procedure has been previously described (8, 9).
Comparison assay: We compared results by EIA with those by the DNA polymerization assay already in use in our laboratory. This assay is based on the method of Mertelsmann et al. (8) but includes an ATP inhibition modification (9). All chemicals were An grade or better.
Results
Precision: Seven control samples were each analyzed in replicates of five over a four-assay period, i.e., 20 assays of each ( Table 1) . For TdT in concentrations ranging from 3.0 to 23 g/L, the within-assay CV was approximately 5%. The between-assay CV ranged from 6.0 to 15.7%. Reference interval: TdT by EIA and by the biochemical assay with isolated MNC from patients with nonmalignant disease yielded <50 ng per 10 MNC and <0.1 U per 10 MNC, respectively.
For a small group of patient controls from whom we had bone-marrow specimens, the TdT concentration (by EIA) was <160 ng per 108 MNC. The observed upper reference interval limits of 50 and 160 ng per iO MNC for whole blood and bone marrow, respectively (in normal and nonleukemic lymphocytes), are in agreement with previous findings (20) . However, the number of patients in our control group was too small for the data to be used in establishing reference intervals. Therefore we used the upper reference interval limits recommended by Abbott Laboratories for whole blood and bone marrow: 100 and 320 ng per 108 MNC, respectively. The upper reference limit of normality for bone-marrow specimens as determined by enzymatic DNA polymerase assay was 0.2 U per 108 MNC.
Correlation of TdT as measured by enzymatic DNA polymerase and EM: MNC isolated from 142 samples of bone marrow and 107 samples of peripheral blood were analyzed by both the enzymatic and ELA procedures. All points represent average values for duplicate analyses. The overall correlation coefficient for the combined 249 samples was 0.87. Figure 1 indicates the linear regression analysis of the TdT by EIA and enzymatic DNA polymerase assay.
Clinical distribution of data: Table 2 indicates the distribution of TdT (as measured by EIA) in MNC isolated from samples of whole blood and bone marrow of patients in several disease categories. Increased concentrations (>100 ng per 108 MNC) were seen in almost all extracts of blood from patients with active ALL, except for four patients in ALL remission. Only occasionally was TdT increased in acute myelocytic, acute myelomonocytic, or chronic lymphocytic and myelogenous leukemia. In three of 16 patients with lymphoma, the TdT exceeded 100 mg per 108 MNC. For all 26 specimens from normal individuals, TdT concentrations were 100 ng per i0 MNC. TdT in bone-marrow samples from patients with newly active (diagnosed or relapsed) ALL was increased; in most patients with CML none was detected, as was also the case for 20 of 22 patients with lymphoma. Figure 2 shows values for TdT, by both the polymerase assay and EIA, in MNC isolated from peripheral blood and bone marrow, respectively, in various diseases. By either assay, nine of 10 patients with active ALL showed increased values for TdT in peripheral blood. In patients with ALL and CML, at various stages of disease, there was excellent concordance between the two procedures, as also was true in general for TdT in bone marrow.
DIscussIon
TdT, a normal constituent of hematopoietic cells, has been utilized as a specific intracellular marker for immature lymphocytes and is a useful diagnostic and management aid for various types of leukemia (7, 10, 25, 27 #{176}One with autoimmunedisease and seven with myelodysplasticsyndrome. dOne with anemiaor coagulationproblem, three with solid tumor (nonlymphoma), and three with myelodysplastic syndrome. variability that may have contributed to the conclusion that enzymatic DNA polymerase activity correlates poorly with the disease state (30).
The improved reproducibility of the TdT-EIA procedure is related to the simplification of the TdT extraction procedure from whole-blood lymphocytes and increased stability of TdT when measured by EIA as opposed to polymerase activity.
The linear regression equation, y = 2.5x + 116, indicates some scatter of the data; this is not unexpected, considering the limitations of the polymerase assay and differences in assay procedure (i.e., measurements of enzyme activity vs mass) and conditions. There being no "gold standard" for measuring TdT, the concordance of clinical data demonstrates a reasonable equivalence between the enzymatic DNA polymerase and EJA procedures.
The efficacy of the EIA method is demonstrated by the distribution of TdT isolated from MNC in bone marrow and whole blood from individuals with a wide variety or various stages of hemathpoietic diseases.
Of particular interest is the concentration of TdT in patients with CML in blast crisis. Only 11% of whole-blood and 33% of bone-marrow samples from these patients had increased concentrations of TdT. The latter observation is consistent with that reported by McCaflhey et al. (23) , who found that only a subset of blastic CML patients (about 30%) were TdT positive. The need to identify TdT-positive patients with CML in blast crisis is obviously important for predicting response to therapy, and additional studies with a larger number of patients will be needed to verify the effectiveness of TdT as a marker of blast crisis.
The increases of TdT measured by EIA in the bone marrow of two of nine patients with acute myelomonocytic leukemia and in one of six whole-blood specimens, are in accord with previous reports (11, 12) . It has been suggested that the relatively small number of patients in this subset may actually represent an aberrant expression of myeloid The EIA procedure is quantitative and reproducible, does not involve isotopes, permits the use of positive and negative qualitycontrol materials that can be stored frozen for long periods (20) , and can be performed on whole-blood samples. We conclude that the TdT-EIA procedure is a useful analytical tool for the differential diagnosis and monitoring of human leukemia.
